FDA warns Teva over Copaxone ads

03/19/2012 | Pharmalot.com

Teva's Copaxone display at a recent American Academy of Neurology meeting and a website promoting the multiple sclerosis treatment overstate the drug's safety and efficacy, FDA Office of Prescription Drug Promotion officials said in a letter. Moreover, the website did not include risk information in the text of the Web pages and instead included links to other pages, which the OPDP found misleading.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Fort Worth, TX
Director, Senior Legal Counsel
Fort Worth, TX
Corporate Counsel - Healthcare Law Group
South San Francisco, CA
Manager/Senior Manager, Health Services Analytics
Avalere Health
Washington, DC